Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 806,981
  • Shares Outstanding, K 43,550
  • Annual Sales, $ 49,110 K
  • Annual Income, $ -66,820 K
  • 60-Month Beta 1.11
  • Price/Sales 12.40
  • Price/Cash Flow N/A
  • Price/Book 2.05
Trade MRUS with:

Options Overview Details

View History
  • Implied Volatility 125.75% ( -20.73%)
  • Historical Volatility 110.08%
  • IV Percentile 96%
  • IV Rank 70.57%
  • IV High 156.55% on 05/25/22
  • IV Low 51.87% on 08/06/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 1,169
  • Volume Avg (30-Day) 289
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 4,861
  • Open Int (30-Day) 1,931

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.65
  • Number of Estimates 5
  • High Estimate -0.59
  • Low Estimate -0.80
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +8.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.47 +37.62%
on 05/26/22
22.01 -15.81%
on 04/28/22
-3.28 (-15.04%)
since 04/27/22
3-Month
13.47 +37.62%
on 05/26/22
30.26 -38.76%
on 03/02/22
-8.24 (-30.78%)
since 02/25/22
52-Week
13.47 +37.62%
on 05/26/22
33.09 -44.00%
on 12/31/21
-2.52 (-11.97%)
since 05/27/21

Most Recent Stories

More News
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be...

MRUS : 18.53 (+32.55%)
Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround

Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

MRUS : 18.53 (+32.55%)
Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...

MRUS : 18.53 (+32.55%)
Merus to Present at the H.C. Wainwright Global Investment Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

MRUS : 18.53 (+32.55%)
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 18.53 (+32.55%)
PULM : 5.18 (+2.98%)
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host...

MRUS : 18.53 (+32.55%)
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a...

MRUS : 18.53 (+32.55%)
7 Top-Rated Biotech Stocks to Buy for Q2

These stocks don’t depend on typical economic cycles to thrive

MRUS : 18.53 (+32.55%)
BCRX : 9.76 (+7.85%)
MRNA : 147.66 (+8.73%)
ITOS : 17.09 (+1.48%)
BNTX : 166.96 (+5.57%)
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung...

MRUS : 18.53 (+32.55%)
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

MRUS : 18.53 (+32.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 24.22
2nd Resistance Point 21.47
1st Resistance Point 20.00
Last Price 18.53
1st Support Level 15.78
2nd Support Level 13.03
3rd Support Level 11.56

See More

52-Week High 33.09
Fibonacci 61.8% 25.59
Fibonacci 50% 23.28
Fibonacci 38.2% 20.96
Last Price 18.53
52-Week Low 13.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar